Complement factor B inhibitor
Iptacopan
Brand names: Fabhalta
Adult dose
Dose: 200mg PO BD
Route: PO
Frequency: BD
Clinical pearls
- Paroxysmal nocturnal haemoglobinuria — oral alternative to IV anti-C5 mAbs
- Vaccinate against meningococcal/pneumococcal/Hib ≥2 weeks before initiation
Contraindications
- Active Neisseria meningitidis infection
- Lack of meningococcal vaccination
Side effects
- Headache
- UTI
- Diarrhoea
- Increased serious infection risk (encapsulated organisms)
- Hyperlipidaemia
Interactions
- Strong CYP3A4 inducers
Monitoring
- Lipids
- LDH
- Hb
- Infection signs
Reference: BNF; NICE TA976; SmPC; https://bnf.nice.org.uk/drugs/iptacopan/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Insulin Correction Factor (ICF/ISF) · Insulin Management
- R Factor for Drug-Induced Liver Injury (DILI) · Liver Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO